Postmenopausal Hormone Therapy and Systemic Lupus Erythematosus
Authors: Jill P. Buyon
Journal: Annals of Internal Medicine (1995)

Letters15 December 1995Postmenopausal Hormone Therapy and Systemic Lupus ErythematosusJill P. Buyon, MD, H. Michael Belmont, MD, and Kenneth C. Kalunian, MDJill P. Buyon, MDHospital for Joint Diseases, New York, NY 10003; University of California, Los Angeles, School of Medicine, Los Angeles, CA 90033Search for more papers by this author, H. Michael Belmont, MDHospital for Joint Diseases, New York, NY 10003; University of California, Los Angeles, School of Medicine, Los Angeles, CA 90033Search for more papers by this author, and Kenneth C. Kalunian, MDHospital for Joint Diseases, New York, NY 10003; University of California, Los Angeles, School of Medicine, Los Angeles, CA 90033Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-12-199512150-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We congratulate Sanchez-Guerrero and colleagues [1] for investigating postmenopausal estrogens and the risk for systemic lupus erythematosus [1]. Given the preponderance of the disease in women, adverse effects of the female gender and sex hormones in murine lupus, and numerous retrospective reports (often anecdotal and uncontrolled) describing a temporal association between estrogen exposure and the development or exacerbation of the disease, it is easy to accept that estrogens and systemic lupus erythematosus simply do not mix. Accordingly, the finding of an increased relative risk for the disease in a “naive” cohort exposed to postmenopausal estrogens is intuitive. ...References1. Sanchez-Guerrero Jorge, Liang Matthew H., Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122:430-3. LinkGoogle Scholar2. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062-70. CrossrefMedlineGoogle Scholar3. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al . Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-75. CrossrefMedlineGoogle Scholar4. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60:221-5. CrossrefMedlineGoogle Scholar5. Arden NK, Lloyd M, Spector TD, Hughes GR. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus. 1994;3:11-3. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Jill P. Buyon, MD; H. Michael Belmont, MD; Kenneth C. Kalunian, MDAffiliations: Hospital for Joint Diseases, New York, NY 10003; University of California, Los Angeles, School of Medicine, Los Angeles, CA 90033 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOBSOLETE: Environment/Drug-Induced Human Autoimmune DiseaseEnvironment/Drug-Induced Human Autoimmune DiseaseEnvironment/Drug-induced Human Autoimmune DiseaseHormonal regulation of B-cell function and systemic lupus erythematosusSex Hormones and SLE: Influencing the Fate of Autoreactive B CellsReproductive health in SLE 15 December 1995Volume 123, Issue 12Page: 961KeywordsEstrogensLupus erythematosusRandomized trialsRelative riskRetrospective studiesSafety studiesSex hormonesSexual identityStable coronary artery diseaseSystemic lupus erythematosus ePublished: 15 August 2000 Issue Published: 15 December 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...